Helix Biopharma Corp
TSX:HBP
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Helix Biopharma Corp
PP&E Gross
Helix Biopharma Corp
PP&E Gross Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | PP&E Gross | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Helix Biopharma Corp
TSX:HBP
|
PP&E Gross
CA$1k
|
CAGR 3-Years
-71%
|
CAGR 5-Years
-62%
|
CAGR 10-Years
-43%
|
|
|
B
|
Bright Minds Biosciences Inc
CNSX:DRUG
|
PP&E Gross
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Aurinia Pharmaceuticals Inc
NASDAQ:AUPH
|
PP&E Gross
$79.6m
|
CAGR 3-Years
110%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
X
|
Xenon Pharmaceuticals Inc
NASDAQ:XENE
|
PP&E Gross
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Eupraxia Pharmaceuticals Inc
TSX:EPRX
|
PP&E Gross
CA$987.1k
|
CAGR 3-Years
12%
|
CAGR 5-Years
25%
|
CAGR 10-Years
N/A
|
|
|
e
|
enGene Holdings Inc
NASDAQ:ENGN
|
PP&E Gross
$10.2m
|
CAGR 3-Years
198%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Helix Biopharma Corp
Glance View
Helix BioPharma Corp. is an immuno-oncology company, which develops products for the treatment and prevention of cancer. The company is headquartered in Richmond Hill, Ontario and currently employs 10 full-time employees. Helix’s proprietary technological platforms include DOS47, V-DOS47 and L-DOS47. The DOS47 is an oncology platform that offers a debilitation and destruction of cancer cells by modulating the tumor microenvironment. DOS47 is designed to stimulate an increase in the pH of the microenvironment surrounding the cancerous cells, effectively reversing the acidic extracellular conditions that are believed to act to defend the tumor. L-DOS47 is an antibody protein conjugate where the urease component enzymatically converts naturally occurring urea to ammonia. The L-DOS47 drug molecule includes a specialized camelid-derived single domain antibody. V-DOS47 targets the vascular endothelial growth factor two receptor (VEGFR2) and can be used in several types of solid tumors.
See Also
What is Helix Biopharma Corp's PP&E Gross?
PP&E Gross
1k
CAD
Based on the financial report for Jan 31, 2026, Helix Biopharma Corp's PP&E Gross amounts to 1k CAD.
What is Helix Biopharma Corp's PP&E Gross growth rate?
PP&E Gross CAGR 10Y
-43%
Over the last year, the PP&E Gross growth was -90%. The average annual PP&E Gross growth rates for Helix Biopharma Corp have been -71% over the past three years , -62% over the past five years , and -43% over the past ten years .
